Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

69results about How to "Weak immunogenicity" patented technology

Method for inhibiting HIV-1 infectious agent from infecting primary lymphocyte by utilizing CRISPR/Cas9

The invention discloses a method for inhibiting HIV-1 infectious agent from infecting primary lymphocyte by utilizing CRISPR / Cas9 and relates to genetic engineering and an anti-virus infection technology. According to the method, by utilizing the latest CRISPR / Cas9 nuclease system, through the combination of Ad5F35 mosaic type adenovirus vectors of efficient targeted primary T lymphocyte, by editing CCR5 expression of human CD4+T lymphocyte, HIV-1 virus infection is effectively inhibited. According to the method, the CRISPR / Cas9 system is packaged by utilizing the Ad5F35 type adenovirus vectors, the advantages of the CRISPR / Cas9 system and the Ad5F35 type adenovirus vectors are organically combined, the novel method for resisting HIV-1 virus infection is provided, and the method has the potential for being applied for HIV-1 gene treatment research; meanwhile, the Ad5F35 type adenovirus vectors carrying with the CRISPR / Cas9 system can be used for conducting targeted editing to other genes in the primary lymphocyte or gene editing research of other hematopoietic system cells.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI

Chimeric antigen receptor targeting BCMA and application thereof

The invention relates to a chimeric antigen receptor targeting BCMA, which comprises an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, wherein the extracellular domain is an anti-BCMA single domain antibody; wherein the amino acid sequence of the anti-BCMA single domain antibody is selected from: (a) an amino acid sequence as shown in SEQ ID NO. 1; or (b) a variant which is formed by substitution, addition or deletion of one or more amino acids in the amino acid sequence shown in SEQ ID NO. 1 and which is capable of specifically binding to the chimeric antigen receptor and has a function of binding to BCMA and inducing T cell signaling conduction. The chimeric antigen receptor has smaller clinical side effects and highersafety, can effectively reduce solid tumor focus and effectively improve the treatment effect of tumors.
Owner:GUANGZHOU BIO GENE TECH CO LTD

Nano-antibody GN1 specifically combined with GPC3 protein and preparation method and application thereof

The invention relates to the technical field of biology, in particular to a nano-antibody GN1 specifically combined with a GPC3 protein. The nano-antibody GN1 is composed of a variable region of a heavy-chain antibody, the variable region of the heavy-chain antibody comprises an antigenic determinant complementary region and a skeleton region, the skeleton region is selected from the group consisting of FR1, FR2, FR3 and FR4 and homologous sequences thereof, the antigenic determinant complementary region is selected from the group consisting of CDR1, CDR2 and CDR3 and homologous sequences thereof, the amino acid sequences of the CDR1 to the CDR3 are shown in the formulas of SEQ ID NO. 1 to SEQ ID NO. 3, the amino acid sequences of the FR1-4 are shown in formulas of SEQ ID NO. 4-7, the amino acid sequence of the antibody is shown in the formula of SEQ ID NO.8, and the nucleotide sequence for encoding the amino acid is shown in the formula of SEQ ID NO.9. The nano-antibody GN1 can be specifically combined with hepatoma carcinoma cells highly expressing the GPC3 protein to inhibit hepatoma carcinoma cell proliferation. The amino acid sequence of the nano-antibody GN1 or the nucleotidesequence of the nano-antibody GN1 or the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 or the recombinant cell containing the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 can be applied to research and development of diagnostic reagents and drugs for treating liver cancer.
Owner:GUANGXI UNIVERSITY OF TECHNOLOGY

Extractive of bdella and/or lumbricus with the molecular weight below 5800 dalton

The invention provides a kind of extract with its molecular weight being lower than 5800 dalton from hirudo and / or lumbricus, the preparation method, medicine compound and its application. The mentioned extract is better than current hirudo and / or lumbricus extract in terms of visible foreign matter and insoluble micro-particle and product safety. The product in this invention can be used to produce medicine for preventing and treating thrombus relevant diseases.
Owner:李振国

Nano-antibody aiming at procalcitonin and application thereof

The invention relates to the technical field of biomedicines and clinical diagnosis and discloses a novel nano-antibody aiming at procalcitonin (PCT), a coding sequence of the novel nano-antibody andapplication of the novel nano-antibody to diagnosis. According to the novel nano-antibody provided by the invention, camels are immunized by utilizing the procalcitonin to obtain a high-quality nano-antibody gene library; then an enzyme-coupled plate is coated with the PCT to display a correct space structure of protein; the PCT is used as an antigen for screening a camel heavy-chain antibody bacteriophage display gene library, so that a nano-antibody gene aiming at the PCT is obtained; then the gene is transformed into escherichia coli and a nano-antibody strain which can be efficiently expressed in the escherichia coli is established. According to the novel nano-antibody provided by the invention, two different antigen epitopes, which can be combined with the nano-antibody, in the PCT are finally determined, and the nano-antibody has good specificity and stability; furthermore, the obtained nano-antibody is coated and labeled and a detection method of the PCT is established; a firm foundation is provided for researches and development of a PCT clinical diagnosis kit.
Owner:北京科卫临床诊断试剂有限公司

Tumor-targeted zinc-based metal-organic framework drug carrier and preparation method thereof

The invention relates to a tumor-targeted zinc-based metal-organic framework drug carrier. The drug carrier comprises a zinc-based metal-organic framework and folic acid molecules, wherein the zinc-based metal-organic framework is formed by a solvent thermal reaction between zinc nitrate and a 2-amino-1,4-terephthalic acid and has a molecular formula of Zn4O (C8H5NO4)3, and the folic acid molecules are coupled to the zinc-based metal-organic framework through a modification method after synthesis. The invention also provides a preparation method of the tumor-targeted zinc-based metal-organic framework drug carrier. The drug carrier disclosed by the invention can be prepared from raw materials wide in sources, the preparation method is simple and the drug loading capacity is extremely high. The tumor-targeted zinc-based metal-organic framework drug carrier disclosed by the invention has a dual function of passive targeting of EPR (Electron Paramagnetic Resonance) and active targeting of folic acid so that the drug-carried tumor-targeted zinc-based metal-organic framework is effectively targeted and concentrated in a tumor site, thereby achieving an aim of targeted treatment and remarkably reducing the dosage and toxic and side effects of an anti-tumor drug.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Composition based on stem cells and application thereof in preparing preparation for coronary heart disease

The invention discloses a composition based on stem cells and application thereof in preparing preparation for the coronary heart disease. The composition based on the stem cells includes the stem cells prepared through an optimizing method and cell preserving liquid serving as a solvent. Firstly, proper stem cells are selected; secondly, the selected stem cells are further processed through the optimizing method; lastly, the stem cells are collected and resuspended in the cell preserving liquid. A various cell implanting method is adopted in the application of the composition based on the stem cells in preparing the preparation for the coronary heart disease, the time nodes before an operation, during the operation and after the operation are combined, and it is ensured that the transplanted stem cells can give the full play. The optimizing method is used for preparing the stem cells and the stem cell composition in the cell preserving liquid, the ventricle function can be extremely obviously enhanced after cell transplantation, and the left ventricle reconstitution is restrained. The optimal cell composition is provided for treating the coronary heart disease, the source is wide, preparation is simple, toxic and side effects are avoided, and the transplanting effect is good.
Owner:奥思达干细胞有限公司

Active polypeptide with antagonistic chemotactic factor receptor CCR5 and preparation method and application thereof

InactiveCN102146132AAnti-chemokine receptor CCR5 activity is goodFunction increasePeptide/protein ingredientsAntipyreticAntiinflammatory drugTarget peptide
The invention discloses an active polypeptide with an antagonistic chemotactic factor receptor CCR5, which has an amino acid sequence in SEQ ID NO:1 or an amino acid sequence obtained by carrying out deletion, addition, insertion and substitution of one or more amino acid residues on the amino acid sequence in SEQ ID NO:1. The invention also discloses a preparation method of the polypeptide, which comprises the following steps of: searching related protein sequences in a database; carrying out multiple alignment comparative analysis to screen out a highly conservative region for combination of a vMIP-II receptor; eliminating interference of unrelated residues through analysis simulation means; determining a target peptide sequence; synthetizing the active polypeptide by a solid-phase synthesis method; and finally testing the bioactivity of the polypeptide. The polypeptide can be used as a CCR5 receptor antagonist for the development of an anti-inflammatory drug, can be used as a lead drug for treating AIDS (Acquired Immune Deficiency Syndrome) and can also be used as a medicament with the immune regulation effect or a medicament for improving the functions of an immune system of an organism.
Owner:JINAN UNIVERSITY

Method for preparing rabbit acellular tracheal matrix

The invention provides a method for preparing a rabbit acellular tracheal matrix. The method includes the following steps: using a fresh rabbit trachea as a raw material, permeating and dissolving insterile distilled water at 4 DEG C for 48 hours, entering a first decellularization cycle: soaking in 4% w / v (g / ml) of a sodium deoxycholate solution, and placing in shaking table at 20 DEG C for performing incubation for 4 h; rinsing with sterile PBS for twice, then placing in 1 mol / L NaCl containing Dnase I at a concentration of 50 kU / mL, continuously shaking for 3 h to dissolve a nucleus and degrade DNA, and finally rinsing twice with the PBS; and performing a next decellularization cycle in the same procedure, and totally performing treatment of two cycles. The method unexpectedly discovers that through improved DEM treatment, it is only required to prepare an acellular matrix similar in structure of an original trachea in the two cycles, mucosal epithelial cells are completely removed, a few chondrocytes remain, a structure is complete, the immunogenicity is weak, infiltration of inflammatory cells is less, the clinical preparation time is shortened, and a treatment basis and hopeare provided for patients who need emergency tracheal stents.
Owner:YANGZHOU UNIV

Preparation method and application of sclerostin single-chain antibody

The invention provides a preparation method and application of a sclerostin single-chain antibody. The preparation method comprises the following steps: extracting anti-SOST monoclonal antibody 5H3D1hybrid tumor cell total RNA; amplifying the antibody light-chain variable region gene and heavy-chain variable region gene by an RT-PCR method; introducing Linker3 between genes VL and VH by an overlapping extending splicing PCR method; forming the single-chain antibody SOST-scFv through connection. The scFv gene with the correct sequencing is cloned to an expression vector PET-22b(+) and is thentransferred into E.coliBL21 for solubility expression; polyacrylamide gel electrophoresis SDS-PAGE is used for identifying expression products; ELISA and West-blot are used for detecting the reactionactivity of the expression protein. The preparation method and the application have the advantages that the molecular weight is small; the permeability is high; the antigen combination activity is high; the bone generation is obviously promoted; the bone loss is inhibited.
Owner:GENERAL HOSPITAL OF PLA

EpCAM single-domain antibody D7

The invention belongs to the field of molecular biology, and specifically relates to an epithelial cell adhesion molecule (EpCAM) single-domain antibody and a nucleotide sequence for encoding the antibody. A phage display technology is utilized, a single-domain heavy chain antibody library capable of specifically binding to a target antigen EpCAM is screened from a single-domain heavy chain antibody library immunized with alpaca, a coding sequence of positive clone is further introduced into a prokaryotic expression vector, and therefore the high-expression EpCAM single-domain antibody is obtained. The antibody disclosed by the invention provides a basis for clinic of targeted immunological therapy of the EpCAM.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL

Affinity short peptide for targeted recognition of Annexin A2 and preparation method and use of affinity short peptide

The invention relates to affinity short peptide for the targeted recognition of Annexin A2 and a preparation method and use of the affinity short peptide. The affinity short peptide can specifically target Annexin A2, and especially the new possibility is provided for the efficient and targeted recognition of tumor tissues and the prediction and improvement of tumor targeted therapy based on the characteristic of high expression of Annexin A2 in most tumors. The polypeptide can be used as a polypeptide molecular probe, or a tumor-directing polypeptide which can be coupled with an anti-tumor drug, is used as a target head to increase the content of the drug or drug-loaded carriers such as a nano-material, liposome and the like in cells over-expressing Annexin A2, and is added with a pharmaceutically acceptable auxiliary material or adjuvant to prepare a novel and more effective targeted anti-cancer drug. The polypeptide provided by the invention can also be prepared into an imaging agent for targeted therapy and imaging of various tumors with high expression of Annexin A2, and can also be prepared into a polypeptide inhibitor for blocking the interaction between Annexin A2 and related proteins. The polypeptide has the specific targeting effect on Annexin A2 and is high in selectivity. The peptide involved in the invention can be prepared through a chemical synthesis method, andis high in purity, small in molecular weight, high in specificity, free of immunogenicity, and safe and reliable.
Owner:辽宁医学诊疗科技研发中心有限公司

Extracting method of dog adipose-derived stem cells, and preparation and application of dog adipose-derived stem cells

The invention discloses an extracting method of dog adipose-derived stem cells, and a preparation and application of the dog adipose-derived stem cells. The preparation for treating dog chronic nephrosis is prepared from the dog allogeneic adipose-derived stem cells. The extracting method of the adipose-derived stem cells comprises the steps: the dog abdominal adipose tissue is obtained, digesting, filtering and centrifuging are conducted, red blood cell lysis buffer resuspending is conducted, and the cells of P0-P3 generations are cultured; and the obtained adipose-derived stem cells of the P3 generation are subjected to surface antigen testing, the adipose-derived stem cells which have more than 70% of CD29 and MHC-1 expressions, less than 2% of CD34 and CD45 expressions, and the high differentiative potential, achieve adipogenesis, osteogenesis and chondrogenesis, and have normal chromosomes, feminine endotoxin and nont-detected mycoplasma are screened out and resuspended with the dosage of 1*10<6> cells/kg-5*10<6> cells/kg through normal saline of 0.5-1.0 mL to prepare the application of the dog allogeneic adipose-derived stem cells, and the preparation is used for treating dogchronic nephrosis. The stem cell preparation is weak in immunogenicity and is not involved in argument in the aspects of society, ethic and law; a transplanted person does not need to provide autologous stem cells, and nearly no damage is caused; and a separating method is simple, and the cells are very high in activity and easy to increase massively.
Owner:NANJING AGRICULTURAL UNIVERSITY +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products